Evogene (EVGN) Tops Q2 EPS by 5c

Evogene (NASDAQ: EVGN) reported Q2 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $470 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• NVE Corporation names new CEO and expands board to seven members